WASHINGTON – Sen. Chuck Grassley of Iowa is asking the Securities and Exchange Commission to inform him of any findings if the agency reviews whether Vertex Pharmaceuticals Inc. executives might have taken advantage of erroneous information to profit from stock sales. Grassley expressed concern about news reports describing a stock sale and price spike after the company announced preliminary data from a clinical trial of a cystic fibrosis drug.
Grassley’s letter to the Securities and Exchange Commission is available here.